DPP-4 inhibitors × glycemic control

TrialDiabetes, obesity & metabolism2019

Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.

Julio Rosenstock et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 883 people · 2019

No range given

Reported lower glycemic control, no range given

−0.51

As reported

difference −0.51, no interval

One number in the abstract

the abstract, start to end

plus metformin (mean difference -0.51; P = .0009).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−0.51
MetforminSGLT2 inhibitorsDPP-4 inhibitorsGlycemic control
1 / 3

16 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 31144431